Rapport Therapeutics, INC 8-K filings

Rapport Therapeutics announced second quarter 2026 financial results, highlighting the initiation of its Phase 3 RAP-219 program for focal onset seizures and continued pipeline advancement.

Rapport Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Rapport Therapeutics reported Q1 2026 financials, highlighting progress in its RAP-219 epilepsy program, a new collaboration, and an extended cash runway.

Rapport Therapeutics announced sustained seizure reduction results from the Phase 2a follow-up period of its RAP-219 trial.

Rapport Therapeutics, Inc. filed a prospectus supplement to register the offer and sale of up to $110 million in common stock through sales agents.

Rapport Therapeutics announced accelerated Phase 3 initiation for its epilepsy drug RAP-219, expanded its epilepsy portfolio, and provided pipeline updates.

Rapport Therapeutics announced positive Phase 2a results for RAP-219 in focal onset seizures, bolstered its balance sheet with a $269.4 million public offering, and reported Q3 2025 financials.

Rapport Therapeutics, Inc. announced an underwritten public offering of 9.6 million common shares, aiming to raise approximately $234.7 million to fund clinical trials and general corporate purposes.

Rapport Therapeutics, Inc. has terminated the sales agreement prospectus for its at-the-market offering, temporarily halting common stock sales under the existing agreement.

Rapport Therapeutics announced positive topline results from its Phase 2a clinical trial of RAP-219 for drug-resistant focal onset seizures, demonstrating statistically significant efficacy and good tolerability.

Rapport Therapeutics announced its second quarter 2025 financial results and provided a business update, highlighting progress in its RAP-219 clinical programs and a cash runway through late 2026.

Rapport Therapeutics, Inc. announced that its stockholders approved the election of three Class I directors and ratified PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025, at the 2025 Annual Meeting.

Rapport Therapeutics announced its lead drug candidate, RAP-219, has fully enrolled its Phase 2a trial for refractory focal epilepsy, with topline results anticipated in September 2025, alongside positive Phase 1 safety data and a strong financial position.

Rapport Therapeutics announced its Q1 2025 financial results and provided a business update, highlighting the progress of its RAP-219 clinical trials and upcoming milestones.

Rapport Therapeutics reports promising financial results for 2024, highlighted by a strong cash position and advancements in their RAP-219 clinical trials for neurological disorders.

Rapport Therapeutics provides a corporate presentation with clinical trial timeline updates and announces the appointment of Dr. Jeffrey Sevigny as Chief Medical Officer.

Rapport Therapeutics reports positive results from its PET and MAD-2 trials for RAP-219, showing target receptor occupancy and good tolerability, while also announcing the departure of its Chief Medical Officer.

Rapport Therapeutics reported its third quarter 2024 financial results, provided a business update, and announced the appointment of new board members.

Rapport Therapeutics announced its second quarter 2024 financial results, highlighted by a successful IPO and progress in clinical trials for their lead drug candidate, RAP-219.

Rapport Therapeutics finalized a private placement of common stock with existing investors, coinciding with its initial public offering.